

Friday, April 19, 2024

Oral Session 1: Clinical & Translational Research

Session Chairs: **Petra Langerbeins & Loïc Ysebaert**

09:30 – 09:45	Ibrutinib lead-in followed by venetoclax plus ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemia	Ilaria Romano	Institute of Oncology Research (IOR), Bellinzona (CH)
09:45 – 10:00	Incidence of Richter transformation in patients with chronic lymphocytic leukemia (CLL): a cohort study evaluating different therapeutic eras	Paul J. Hampel	Mayo Clinic, Rochester (USA)
10:00 – 10:15	Prevalence and clinical impact of clonal hematopoiesis in chronic lymphocytic leukemia	Riccardo Moia	Università del Piemonte Orientale, Novara (IT)
10:15 – 10:30	Preclinical efficacy of the BCL2i venetoclax combined with MEKi cobimetinib or SYKi entospletinib in BTKi-refractory CLL patients harboring BTK mutations	Stephen Martindale	Dana-Farber Cancer Institute, Boston (USA)
10:30 – 10:45	Targeting NF-κB-inducing kinase (NIK) in chronic lymphocytic leukaemia	Iona Ashworth	Brighton and Sussex Medical School, Falmer (UK)
10:45 – 11:00	The Gene Expression Landscape of BTK Inhibitor Treatment in Chronic Lymphocytic Leukemia Exposed by Shallow Depth RNA Sequencing	Thi Huong Lan Do	University Hospital Zurich (CH)

Oral Session 2: Translational and Basic Research

Session Chairs: **Deborah Stephens & Michael Hallek**

11:30 – 11:45	TLR9 signaling is a potential tumor escape mechanism following B-cell receptor targeted treatments in subsets of	Emma Kennedy	Brighton and Sussex Medical School, Falmer (UK)
11:45 – 12:00	BH3 Profiling Identifies Anti-Apoptotic Dependencies and Therapeutic Vulnerabilities in Primary Richter Transformation (RT) Cells and in a Genetically-Engineered Murine Model of RT	Nathalie Javidi-Sharifi	Dana-Farber Cancer Institute, Boston (USA)
12:00 – 12:15	LYN kinase activity and its regulator CSK are key players in CLL supporting macrophages	Viktoria Kohlhas	University Hospital of Cologne, Cologne (GER)

12:15 – 12:30	Impact of Germline and Somatic ATM Variants in Chronic Lymphocytic Leukemia (CLL): Clinical Implications and Response to PARP Inhibition	Kiyomi Mashima	Dana-Farber Cancer Institute, Boston (USA)
12:30 – 12:45	Role of G protein-coupled receptor kinase 2 (GRK2) in the localization and activation of leukemic cells	Chiara Cassarino	Academia Nacional de Medicina, CABA (ARG)
12:45 – 13:00	Rps15-S138F mutation results in translational errors underlying onset of chronic lymphocytic leukemia	Neil Ruthen	Broadinstitute, Cambridge (USA)

Poster Session: Guided Poster Walk

Session Chairs: **Deborah Stephens, Loïc Ysebaert, Petra Langerbeins**

16:50 – 17:00	Adaptation of chronic lymphocytic leukemia to ibrutinib is mediated by epigenetic plasticity of residual disease and by-pass signaling via MAPK pathway	Lodovico Terzi di Bergamo	Institute of Oncology Research (IOR), Bellinzona (CH)
17:00 – 17:10	Combined therapy of endocytosis inhibitors and a novel glycoengineered anti-ROR1 antibody to enhance antibody-dependent cellular cytotoxicity (ADCC) against chronic lymphocytic leukemia	Kamrul Hasan	University of California, San Diego (USA)
17:10 – 17:20	A Comparative Study of Different Macrophage Feeder Systems for the Support of Chronic Lymphocytic Leukemia Survival	Hendrik Jestrabek	University Hospital of Cologne, Cologne (GER)
17:20 – 17:30	CAR T cells generated from CLL patients are characterized by determinants of immune dysfunction that may be positively modulated by treatment with targeted agents	Francesca Perutelli	A.O.U. Città della Salute e della Scienza di Torino, Torino (ITA)
17:30 – 17:40	Venetoclax resistant cells are sensitive to anti-CD20 monoclonal antibodies.	Valeria J. Sarapura Martinez	Academia Nacional de Medicina, CABA (ARG)
17:40 – 17:50	Utility of the international chronic lymphocytic leukemia prognostic index in front-line treatment with targeted drugs	Sandra Robrecht	University Hospital of Cologne, Cologne (GER)

The YIM committee

Petra Langerbeins, Cologne
Deborah Stephens, Chapel Hill
Loïc Ysebaert, Toulouse